Sangamo Therapeutics, Inc. (SGMO) financial statements (2020 and earlier)

Company profile

Business Address 501 CANAL BLVD
RICHMOND, CA 94804
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments36240024314320917993
Cash and cash equivalents80140502269610
Short-term investments28226019312014017383
Restricted cash and investments     0 
Receivables385453113
Prepaid expense   2110
Other current assets     00
Other undisclosed current assets552   1
Total current assets:40541124815021319197
Noncurrent Assets
Property, plant and equipment3079317311
Long-term investments and receivables22 1  4739
Long-term investments22 1  4739
Intangible assets, net (including goodwill), including:929522233
Goodwill394022 22
Intangible assets, net (excluding goodwill)5355   22
Other undisclosed intangible assets, net (including goodwill)    2 
Restricted cash and investments24     
Other noncurrent assets935000 
Other undisclosed noncurrent assets77     0
Total noncurrent assets:23218038855244
TOTAL ASSETS:638590287158217243141
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1821116894
Accounts payable7303463
Accrued liabilities121001 
Employee-related liabilities 95333 
Other undisclosed accounts payable and accrued liabilities107411(0)1
Deferred revenue and credits284992
Contract with customer, liability3948
Other undisclosed current liabilities14953333
Total current liabilities:70794513202110
Noncurrent Liabilities
Liabilities, other than long-term debt941172945167
Deferred revenue and credits2945137
Contract with customer, liability81108
Deferred tax liabilities, net77   1 
Other liabilities62     
Business combination, contingent consideration, liability     2
Other undisclosed noncurrent liabilities4128254  2
Total noncurrent liabilities:1351455485169
Total liabilities:2052239922253719
Stockholders' equity
Stockholders' equity attributable to parent433367188136192207122
Common stock1111111
Additional paid in capital1,091930683576561535423
Accumulated other comprehensive income (loss)(2)(1)(0)0 (0)0
Accumulated deficit(657)(563)(495)(441)(369)(329)(302)
Stockholders' equity attributable to noncontrolling interest01     
Total stockholders' equity:433367188136192207122
TOTAL LIABILITIES AND EQUITY:638590287158217243141

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit:102843719404624
Operating expenses(208)(162)(93)(92)(86)(73)(51)
Operating loss:(105)(77)(56)(73)(47)(27)(27)
Nonoperating income   1000
Other nonoperating income   10  
Loss from continuing operations before equity method investments, income taxes:(105)(77)(56)(72)(46)(26)(27)
Other undisclosed income from continuing operations before income taxes1082    
Loss from continuing operations before income taxes:(95)(69)(55)(72)(46)(26)(27)
Income tax benefit   06  
Net loss:(95)(69)(55)(72)(41)(26)(27)
Net income attributable to noncontrolling interest01     
Net loss available to common stockholders, diluted:(95)(68)(55)(72)(41)(26)(27)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(95)(69)(55)(72)(41)(26)(27)
Other comprehensive loss(2)(1)     
Other undisclosed comprehensive income (loss)1(0)     
Comprehensive loss:(96)(70)(55)(72)(41)(26)(27)
Comprehensive income, net of tax, attributable to noncontrolling interest01     
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  (0)00(0)(0)
Comprehensive loss, net of tax, attributable to parent:(96)(69)(55)(72)(41)(26)(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: